Zevra Therapeutics, Inc.
ZVRA
$8.33
-$0.06-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 605.36% | 481.73% | 495.65% | -6.79% | 27.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 605.36% | 481.73% | 495.65% | -6.79% | 27.63% |
| Cost of Revenue | -46.24% | 246.46% | 668.57% | 11.33% | 1,499.31% |
| Gross Profit | 1,683.41% | 1,441.32% | 486.34% | -8.69% | -49.40% |
| SG&A Expenses | 4.49% | 64.88% | 96.81% | 4.82% | 178.58% |
| Depreciation & Amortization | -79.61% | 4.53% | 5.69% | 109.33% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.29% | 35.29% | 7.75% | -2.20% | 69.78% |
| Operating Income | 115.17% | 48.19% | 73.83% | -1.71% | -77.73% |
| Income Before Tax | 97.06% | 487.34% | 88.52% | -2.39% | -226.05% |
| Income Tax Expenses | -- | 3,041.43% | 1,788.57% | -- | -- |
| Earnings from Continuing Operations | 98.36% | 474.94% | 81.36% | -79.67% | -220.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.36% | 474.94% | 81.36% | -79.67% | -220.49% |
| EBIT | 115.17% | 48.19% | 73.83% | -1.71% | -77.73% |
| EBITDA | 117.65% | 51.97% | 80.38% | 4.19% | -67.88% |
| EPS Basic | 98.60% | 366.41% | 85.60% | -30.09% | -132.83% |
| Normalized Basic EPS | 97.18% | 51.05% | 91.14% | 26.75% | -134.64% |
| EPS Diluted | 98.56% | 357.17% | 85.60% | -30.09% | -132.83% |
| Normalized Diluted EPS | 97.18% | 52.40% | 91.14% | 26.75% | -134.64% |
| Average Basic Shares Outstanding | 17.03% | 30.74% | 29.48% | 38.11% | 37.68% |
| Average Diluted Shares Outstanding | 17.03% | 34.43% | 29.48% | 38.11% | 37.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |